Companies /Healthcare

ARS Pharmaceuticals Inc

NASDAQ: SPRY Biotechnology
$3.65
▼ $0.24 (−6.28%) today
Markets open · 2:35pm ET

SPRY at a Glance

Valuation
Market cap
$391.1M
Profitability
Revenue (TTM)
$122.1M
Profit margin
-163.6%
EPS (TTM)
$-2.01
Price
52-week range
$2 – $13
Street target
$17.00

Headquartered in San Diego, CA Fiscal year ends December NASDAQ: SPRY ars-pharma.com

About ARS Pharmaceuticals

ARS Pharmaceuticals is a commercial-stage biopharmaceutical company focused on needle-free epinephrine for patients and caregivers facing severe allergic reactions.

Its core product is neffy, an epinephrine nasal spray. It is the only needle-free epinephrine approved by the U.S. FDA for emergency treatment of Type I allergic reactions, including anaphylaxis, in adults and children weighing 33 lbs. (15 kg) or more.

Revenue comes from three sources:
- U.S. net product sales of neffy.
- Collaboration revenue from international partners.
- Supply agreement revenue.

Outside the U.S., the product is marketed as EURneffy in the European Union, where it is the only needle-free epinephrine authorized by the European Commission, and as 优敏速 in China, both through partners.

The company is shifting its U.S. commercial approach toward account-based targeting of providers, after discontinuing linear TV and broad consumer advertising.

It is also extending its intranasal epinephrine platform. ARS-2 is in a Phase 2b trial as a potential first on-demand treatment for acute breakthrough flares of chronic spontaneous urticaria. Interim data are expected in Q1 2027.

Management targets cash flow breakeven by the end of 2027. Updated

Latest Activity

SPRYARS Pharmaceuticals
Q3 2026
EPS
-$0.36
est -$0.33-8.0%
Revenue
$38M
est $42M-10.2%

SG&A fell to $43.5 million from $74.8 million a year ago after ARS Pharmaceuticals killed broad consumer advertising, with both lines missing expectations and management reaffirming cash flow breakeven by the end of 2027. Neffy's US market share only moved to 5% from 4%, so the cheaper playbook has to prove it can still buy growth.

Quarterly EPS — reported vs estimate

SPRY Coverage

10:13am ET
Investing

5 Stocks Under $10 Growing 50% Or More

Are you looking for low-cost stocks to add to your portfolio? Doing so can be a challenge. After all, stocks that trade with low share prices are often risky investment opportunities. That’s…

Joshua Rodriguez

Frequently Asked Questions

What does ARS Pharmaceuticals do?

ARS Pharmaceuticals is a commercial-stage biopharmaceutical company focused on needle-free epinephrine for patients and caregivers facing severe allergic reactions. Its core product is neffy, an epinephrine nasal spray.

What is the SPRY stock price target?

The Wall Street consensus 12-month price target for SPRY is $17.00.